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Introduction
The progress of human genome sequencing has revealed the
existence of several hundred orphan G protein-coupled recep-
tors (GPCRs)[1] that are molecularly known receptors but still
lack a defined physiologically significant ligand. The deorphani-
zation of these receptors and the identification of their roles
could be useful to explain novel regulatory mechanisms of
physiological phenomena and to reveal novel drug targets.[1–3]
One such receptor, GPR17, also called the P2Y-like receptor
and R12, was first characterized by Raport and collaborators[4]
in efforts to identify new chemokine receptors. GPR17 has fea-
tures typical of the GPCR superfamily, such as seven transmem-
brane domains (TM1–TM7), eight amphipathic helices, and
a portion of the sites for N-glycosylation, which is essential for
transport from the rough endoplasmic reticulum to the plasma
membrane (Figure 1).
Moreover, the intracellular C-terminus has a PDZ-1-like
region (X-S-X-Ø) that is involved in the interaction of the re-
ceptor with signaling proteins during internalization and recy-
cling. Human GPR17 (hGPR17) is about 90% homologous with
the murine (mGPR17) and rat (rGPR17) forms. It was shown, in
fact, that in the alignment of the amino acid sequences of rat,
mouse, and human GPR17, transmembrane domains TM3,
TM6, and TM7 almost completely overlap. The conservation of
a typical region, TM6 (H-XX-R), which is considered essential
for linking with the ligand and is usually present in GPCRs,
confirms that GPR17 belongs to the GPCR family.[5–7] From
a phylogenetic point of view, the receptor is located in an in-
termediate position between P2Y purinergic and cysteinyl leu-
kotriene receptors (CysLTRs), specifically between P2Y12/13/14Rs
and CysLT1/2Rs (Figure 2).
Conflicting literature data (discussed below) make the func-
tion of GPR17 less certain, though a preponderance of evi-
dence suggests a dual pharmacological profile. Well-known
P2YR and CysLTR antagonists, specifically, the P2Y1R-selective
antagonist 2’-deoxy-N6-methyladenosine 3’,5’-biphosphate
(MRS 2179), the P2Y12/13R antagonist N
6-(2-methyl-thioethyl)-2-
(3,3,3-trifluoropropylthio)-b,g-dichloromethylene-ATP (cangre-
lor), and CysLT1R antagonists montelukast and pranlukast,
The GPR17 receptor is a G protein-coupled receptor (GPCR)
that seems to respond to two unrelated families of endoge-
nous ligands: nucleotide sugars (UDP, UDP-galactose, and
UDP-glucose) and cysteinyl leukotrienes (LTD4, LTC4, and LTE4),
with significant affinity at micromolar and nanomolar concen-
trations, respectively. This receptor has a broad distribution at
the level of the central nervous system (CNS) and is found in
neurons and in a subset of oligodendrocyte precursor cells
(OPCs). Unfortunately, disparate results emerging from differ-
ent laboratories have resulted in a lack of clarity with regard to
the role of GPR17-targeting ligands in OPC differentiation and
in myelination. GPR17 is also highly expressed in organs typi-
cally undergoing ischemic damage and has various roles in
specific phases of adaptations that follow a stroke. Under such
conditions, GPR17 plays a crucial role; in fact, its inhibition de-
creases the progression of ischemic damage. This review sum-
marizes some important features of this receptor that could be
a novel therapeutic target for the treatment of demyelinating
diseases and for repairing traumatic injury.
Figure 1. Representation of hGPR17 structure.
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were found to counteract GPR17 activation in a [35S]GTPgS
binding assay.[8–11]
Cangrelor, which does not act as a GPR17 agonist[8] can in-
stead act as an antagonist, as it completely blocks the activa-
tion of GPR17 by UDP-glucose or LTD4 in a concentration-de-
pendent manner.[8, 9,11–15] GPR17 ligands, structure, pharmaco-
logical activity, and affinity are reported in Table 1.
A homology model of human GPR17 was built using the X-
ray crystal structure of bovine rhodopsin (bRh) as a template.[16]
Two isoforms of the receptor are known, a short form (GPR17-
S, 339 amino acids) and a long form (GPR17-L, 367 amino
acids), which differ in the N-terminus region (Figure 1).[11,16,17]Figure 2. Phylogenetic scheme showing the relationship between GPR17,
P2YR, and CysLTR.
Table 1. Ligand specificity at human (h), rat (r), and mouse (m) GPR17 in [35S]GTPgS binding assays performed in 1321N1-transfected cells.
Compound Pharmacology and affinity
toward GPR17
Compound Pharmacology and affinity
toward GPR17
Agonist
EC50=1.14 mm (h),
4.6 mm (r),
55 nm (m)
Agonist
EC50=0.33 nm (h),
65 nm (r),
0.74 nm (m)
Agonist
EC50=12 mm (h),
530 nm (r),
88 nm (m)
Agonist
EC50=7.2 nm (h),
5.9 nm (r),
0.63 nm (m)
Agonist
EC50=1 mm (h),
n.d.[a] (r),
68 nm (m)
Agonist
EC50=n.d.
[a] (h, r),
0.31 nm (m)
Antagonist
IC50=0.7 nm (h),
22 pm (r),
1.2 nm (m)
Antagonist
IC50=60 nm (h),
196 nm (r),
61 nm (m)
Antagonist
IC50=508 nm (h),
0.18 pm (r),
n.d.[a] (m)
Antagonist
IC50=10.5 nm (h),
31 nm (r),
n.d.[a] (m)
Antagonist
IC50=3.1 mm vs. UDP-glucose,
209.8 vs. LTD4 (h),
n.d.[a] (r, m)
[a] Not determined.
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The different functional properties of GPR17 isoforms were
partly confirmed by Benned-Jensen and Rosenkilde, who re-
ported that GPR17-L was only minimally activated by uracil nu-
cleotides, except for UDP, which was inactive. Similarly, GPR17-
S was activated with similar potencies but slightly lower effica-
cies in comparison with the nucleotide receptors P2Y6R and
P2Y14R.
[12]
GPR17 localization
Both rat and human GPR17 are mainly expressed in the CNS,
in particular on oligodendrocyte precursor cells (OPCs), and in
the kidney and heart, which are organs that typically undergo
ischemic damage, while in contrast, there is a minimal expres-
sion in the liver and lung.[8,9,18,19, 20] Immunohistochemistry
studies in mouse brain performed by Lecca and collaborators
using a specific homemade anti-GPR17 antibody showed that
the GPR17 is expressed by neurons, as demonstrated by co-
staining with neuronal specific markers (i.e. , NeuN and SMI-
311).[9] On the other hand, Chen and co-workers did not find
expression of GPR17 in neurons of adult mouse brain under
basal physiological conditions.[18] This discrepancy could be
due to the specificity of the GPR17 antibodies used for immu-
nohistochemistry. Moreover, no co-localization was found with
cortical astrocytes, as shown by labeling with the specific
marker glial fibrillary acidic protein (GFAP).[9, 21]
In addition, GPR17 is greatly expressed in ependymal cells,
which are located in the hippocampus and in direct contact
with ventricle cavities.[9] Moreover, no co-localization of more
mature myelinating oligodendroglial markers was found with
GPR17. This suggests that GPR17 expression is exclusively seg-
regated to the early stages of the oligodendrocyte differentiat-
ing pathway, and that the receptor is switched off when these
cells achieve functional maturation. Maisel and collaborators
demonstrated that gpr17 is one of the most important genes
present in human adult neuronal precursor cells (NPCs) ;[22] for
this purpose, the presence of GPR17 was studied in mouse
brain neurogenic areas, i.e. , the dentate gyrus (DG) of hippo-
campus and the subventricular zone (SVZ) of lateral ventricles
(LV).[9] In the walls of LV, GPR17 is highly expressed in ependy-
mal cells, which are in direct contact with ventricle cavities.
The reactive GPR17 cells were also found in the hippocampus,
a neurogenic area present in the adult brain.[9] Moreover, it
was demonstrated that GPR17 plays a crucial role in oligoden-
drocyte differentiation. In fact, GPR17 is expressed in primary
cortical neuron-glia cultures by OPCs, together with typical
pre-oligodendroglial markers like NG2 chondroitin sulfate pro-
teoglycan.[8–10,23, 24]
The results showed that OPCs expressing GPR17 represent
a premyelinating phase of oligodendrocyte differentiation and
take part in the brain reaction to acute and chronic le-
sions.[23, 24] Additionally, GPR17 is expressed in the spinal cord,
supporting a role for this receptor in both neurons and oligo-
dendrocytes. GPR17 is expressed, under physiological condi-
tions, in neurons and oligodendrocytes at different phases of
maturation and in ependymal cells lining the central canal, but
it is not expressed in astrocytes.[18,25]
It is important to note that the distribution of the two
GPR17 splicing variants (short, S, and long, L) are about the
same in many different regions of the brain but are less ex-
pressed in the thalamus. Expression levels increase in the fol-
lowing order: hypothalamus<cerebellum<amygdala<cere-
bellar hemisphere< frontal cortex<hippocampus<putamen.
Moreover, both isoforms exhibited higher expression in the pu-
tamen region with respect to the whole brain. An exception is
in the hippocampus area, where hGPR17-S is more highly ex-
pressed.
In the peripheral nervous system, the situation is different,
as the long isoform (hGPR17-L) is expressed at higher levels in
the heart and kidneys, particularly when compared with the
brain, where the level of hGPR17-S is very low. This situation
indicates that GPR17-S plays a principal role in the brain, while
GPR17-L probably adopts this role in the heart and kidneys.
This differential expression profile suggests tissue-specific roles
in humans.[12]
GPR17 pathological role in oligodendrocyte maturation and
myelination processes
As GPR17 is expressed in organs typically undergoing ischemic
damage, its role was explored in a rat animal model of ische-
mic stroke (rat middle cerebral artery occlusion (MCAo))[8] and
in a mouse model.[9] GPR17 plays a differential role that seems
to depend on specific phases of response after stroke (sequen-
tially, death of irreversibly damaged cells, clearance of dead
cells, remodeling, and repair). Upon ischemia induction, there
is a time-dependent upregulation of GPR17, with rapid expres-
sion in neuronal cells nearest the injured area.
Twenty-four hours after MCAo, various neurons overexpress
GPR17; at the same time, co-presence of HSP70, an inducible
marker of cellular stress, injury, and death, suggests that the
GPR17 upregulation is correlated with neuronal death. This
finding was confirmed 48 h after injury, as the lesion site no
longer presented neurons expressing GPR17, presuming the
death of the neurons overexpressing this receptor. The situa-
tion is different 48–72 h after MCAo; in fact, many cells ex-
pressing GPR17 and a marker of activated microglia/macro-
phage (IB4) were present at the borders of the lesioned
area.[26–28]
Seventy-two hours after MCAo, a greater number of OPCs
expressing GPR17 was found in the regions surrounding the is-
chemic area and in the ipsilateral corpus striatum,[9] suggesting
that the proliferation or recruitment of OPC increased in re-
sponse to demyelination. Administration of cangrelor or mon-
telukast, two GPR17 antagonists, during acute injury caused
a reduction in infarct ischemic area.[8,9] The administration of
GPR17 UDP-glucose agonist in a neonatal rat model of ische-
mic periventricular leukomalacia (PVL), in contrast, resulted in
the recovery of myelin sheaths and improved motor func-
tions.[29–31] This incongruity could be due to the different con-
sequence of the ischemic insult in neonatal brain compared
with adults.
In line with these findings, some authors have demonstrated
that oligodendrocytes are very susceptible to brain damage
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and that proliferation of OPCs is identified after ischemia
nearby the lesioned area,[32] likely as a response to demyelina-
tion.[33,34] It is important to note that in the first two weeks
after ischemia, OPCs collect in the peri-infarct area and then
differentiate into mature oligodendrocytes.[35,36] These findings
suggest that GPR17 could be considered a biosensor that is
stimulated by brain injury in several embryonically distinct cell
types with two different time-dependent implications: firstly,
contributing to evolution of the damage, and secondly, in the
remodeling and repair of damage. These assumptions are sup-
ported, moreover, by the role played by endogenous cysteinyl
leukotrienes (CysLTs) and nucleotides, natural ligands of GPR17,
in the injured brain. In fact, following the release of these mol-
ecules from damaged cells, they stimulate the brain through
binding with specific receptors with the objective of resisting
brain damage and, at the same time, initiating repair mecha-
nisms.
Additional studies were performed on spinal cord injury
(SCI) in order to analyze the different time-expression changes
of GPR17.[13] Results showed that SCI induced an intense and
rapid death of neurons and oligodendrocytes that express
GPR17 inside the lesioned area. Successively, 24 h after SCI, ac-
tivated microglia/macrophages migrated toward and infiltrated
the lesioned area, and their number increased over time after
injury.
One week after SCI, this receptor expression decreases, sug-
gesting that the expression of GPR17 is augmented during the
early phases of microglia/macrophage activation, probably due
to enhanced migration to and infiltration of the lesioned area,
followed by downregulation at the end of these processes.
GPR17 is expressed on ependymal cells lining the central
canal, which could support the apparent opposite effects (i.e. ,
cell death and damage repair) mediated by the receptor.[37]
The ependymal cells can be considered the stem cells of the
adult spinal cord, because after injury, they start to proliferate
and to generate astrocytes and oligodendrocytes that migrate
to the lesion area constructing a significant part of the glial cic-
atrix.[38] In the brain, the usually quiescent ependymal cells can
also generate neuroblasts and astrocytes after stroke.[39] As
GPR17 is expressed in ependymal cells, it could play a role in
driving precursor cell specification and differentiation after
brain injury and SCI.
GPR17 seems to be implicated in demyelinating diseases
and represents one of the first potential GPCR drug targets for
demyelinating pathologies of the CNS, such as multiple sclero-
sis (MS). In the case of loss of oligodendrocytes and myelin,
axonal functions are impaired; therefore, in pathologies like
MS, cerebral ischemia, or stroke, new oligodendrocytes are re-
cruited to replace the injured cells and form new myelin
sheets.[40]
After a demyelinating event, there is a spontaneous brain
repair process that can lead to a limited positive neurological
outcome.[41] Therefore, it is crucial to promote oligodendrogen-
esis to facilitate the natural brain repair process. Preclinical
studies confirm that enhancement of endogenous oligoden-
drogenesis in these pathologies by pharmacological and cell-
based therapies facilitates brain repair processes and reduces
neurological deficits. It is broadly known and shared by the
entire scientific community involved in the study of GPR17
that this receptor is implicated in the remyelination process,
but the issue regarding whether such desired pharmacological
effects are due to its activation or inhibition remains unre-
solved. Studies performed in GPR17-overexpressing mice
showed a strong demyelination process, while in the knockout
variant, the myelination process increased.[18] Furthermore, re-
searchers demonstrated that GPR17 is mainly expressed by
OPCs at different levels, depending on their differentiation
state, but in the spinal cord and optic nerve, GPR17 is downre-
gulated during the peak period of myelination and in adult-
hood.[18, 19,42]
Moreover, it was demonstrated that in a mouse model of
MS (demyelination injury induced by experimental autoim-
mune encephalomyelitis [EAE]) that GPR17 is upregulated in
the CNS region where demyelination was occurring.[43] As
GPR17 expression is downregulated during active myelinogen-
esis and upregulated in demyelinating lesions, chances are
that the remarkable expression of this receptor could negative-
ly affect oligodendrocyte myelination. Moreover, experiments
performed to treat cerebellar slice cultures of mice from their
postnatal day with a selective agonist of GPR17 produced
a block of oligodendrocyte maturation and myelination arrest,
due to loss of myelin basic protein (MBP)-positive cells,[44,45] un-
derlining a negative involvement of GPR17 in CNS repair mech-
anisms. It was also demonstrated that the CysLTR antagonists
montelukast and pranlukast have a neuroprotective effect on
cerebral ischemia in rats and mice, proving their usefulness in
the treatment of cerebral ischemia at earlier phases.[46]
Moreover, the administration of montelukast produced an
increase in the proliferation rate of stem cells, leading to
a major pool of cells in the undifferentiated stage.[47] In line
with these findings, administration of UDP-glucose, UDP, or
LTD4 in neurospheres from murine oligodendroglioma cells
produced a decrease in the number of Olig2 oligodendro-
cytes, emphasizing that GPR17 activation promotes cell differ-
entiation.[45]
Recently, Simon and collaborators demonstrated that when
GPR17 is stimulated by an agonist, specifically MDL29951
(Figure 3), there is a decrease in
MBP expression levels, mainly by
the Gai/o signaling pathway, and
a subsequent diminution of ade-
nylyl cyclase-cAMP-PKA-cAMP re-
sponse element-binding protein
(CREB).[48]
In contrast, findings obtained
from other researchers through ge-
netic and pharmacological studies
emphasize that GPR17 activation (by UDP-glucose or LTD4) pro-
motes the transition of OPCs from a pre-immature phenotype
to fully mature cells expressing MBP. Furthermore, inhibition of
the receptor using P2YR or CysLTR antagonists (cangrelor or
montelukast) or specific silencing RNAs inhibited OPC matura-
tion. In some knockout experiments and in cultured OPCs, it
was demonstrated that GPR17 promoted cell differentiation, al-
Figure 3. Chemical structure
of MDL29951.
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though when the cells expressed the pre-oligodendrocyte
marker O4, GPR17 had to be downregulated to allow complete
differentiation. This confirms that GPR17 is not present on
MBP-expressing mature oligodendrocytes.[8, 9,17,23]Additionally, it
was proven that the activation of K+ currents, both in a subpo-
pulation of OPCs and in immature O4+ pre-oligodendrocytes,
is mediated by GPR17. In contrast, this event is not present in
mature oligodendrocytes. This correlates with the GPR17 pat-
tern of dissimilar expression during the maturation of OPCs; in
fact, GPR17 was shown to gradually disappear in late OPCs.[49]
There is evidence of a probable relationship between GPR17
and P2Y12 that plays an important role in cell myelination pro-
cesses. In fact, when GPR17 is downregulated, P2Y12 is upre-
gulated, and the activation of GPR17 promotes cell differentia-
tion toward myelination, while the activation of P2Y12 leads to
cell maturation.[50] More recently, by means of the first GPR17
transgenic reporter mouse, Vigan and collaborators verified
that OPCs express GPR17 in their earlier life. The confocal mi-
croscopy technique used made it possible to visualize the final
destiny of GPR17-expressing precursors.[51] The presence of the
receptor during the maturation of OPCs seems to have a reduc-
tion in a precise maturation time; in fact, its forced expression
at the level of pre-oligodendrocytes led to a decrease in the
maturation and myelination processes, while gpr17 gene si-
lencing promoted the maturation of OPCs to myelinating
cells.[9, 19,27]
The ability of GPR17 to organize lesion remodeling and
repair in human brain was also demonstrated.[38] The receptor
characterization in human brain was performed in neurosurgi-
cal and autoptic samples from patients with traumatic brain
injury (TBI). This resulted in overexpression of the receptor in
OPCs as a consequence of a local injury, probably due to the
release of diffusible factors from damaged cells, as demonstrat-
ed by the fact that overexpression in OPCs was found in all pa-
tients who had died of intracranial complications and only in
20% of patients who died of extracranial complications. In ad-
dition, there was a negative correlation between GPR17 ex-
pression and post-traumatic survival time; in fact, patients who
died after more than 16 days following injury showed a clear
decrease in receptor expression.
In addition to the role of GPR17 in oligodendrogenesis,
a possible implication in allergic pulmonary inflammation has
been reported. Maekawa and collaborators demonstrated that
GPR17 negatively regulates the levels of IgE and specific IgG1
in serum, and the inflammatory cell accumulation in the lung
and in the bronchoalveolar lavage fluid after CysLT1R activa-
tion. The same report further showed a negative modulation
of Th2/Th17 cytokine expression by GPR17 in the lung after in-
tranasal sensitization with a house dust mite (extract of Derma-
tophagoides farinae [Df]) in mice.
Sensitization of wild-type recipients with Df pulsed in den-
dritic cells derived from bone marrow of each genotype re-
vealed an appreciable increase in inflammation of the lungs
and serum IgE in GPR17-deficient mice in comparison with the
wild-type strains; in contrast, there were decreased responses
in CysLT1R-deficient mice. These results highlight a constitutive
downregulation of CysLT1R functions due to GPR17 activation
in both antigen presentation and downstream stages of aller-
gic pulmonary inflammation.[52] Based on these results, GPR17
appears to play a key role in allergic pulmonary inflammation
and also clearly represents a novel target for new TBI thera-
pies, even if its role in the oligodendrogenesis process still re-
mains to be elucidated.
Constitutive and ligand-mediated activities of GPR17
As reported above, GPR17 seems to be activated by CysLTs
and nucleotide sugars, with the inhibition of cAMP production
and intracellular Ca2+ accumulation. Unfortunately, there are
discrepancies between different laboratories, with some report-
ing that GPR17 responds to CysLTs and uracil nucleotides,[8, 53]
and others reporting that it is only activated by CysLTs[44] or
uracil nucleotide ligands.[54] Furthermore, a number of re-
searchers also assert that GPR17 does not respond to either of
the two families of ligands.[55]
According to Ciana and co-workers, LTC4 and LTD4 both acti-
vate GPR17 with EC50 values in the nanomolar range,
[8,56] while
UDP, UDP-glucose, and UDP-galactose activate GPR17 with
EC50 values in the micromolar range. Experiments were carried
out in several cell lines using both [35S]GTPgS binding to puri-
fied membranes and a cAMP accumulation assay in live cells
using a competitive protein binding method, yielding results
that demonstrated agreement between the two ap-
proaches.[8,57] To demonstrate the receptor coupling to a Gi
protein, the authors performed the same experiments in cells
pretreated with the Gi inhibitor pertussis toxin. The toxin fully
inhibited the [35S]GTPgS binding stimulated by agonists and
fully suppressed the agonist effects on forskolin-induced cAMP
formation, indicating a crucial role for Gi protein in GPR17 re-
sponses. The activation of GPR17 by CysLTs has not yet been
verified by independent laboratories and thus remain a contro-
versial matter, even though work published by Marschallinger
and co-workers suggests that the effects of montelukast,
a well-known antagonist of CysLT1R, on neurogenesis and cog-
nition are most likely mediated through inhibition of GPR17,
suggesting a possible involvement of CysLTs in receptor activa-
tion.[58] Moreover, there is further evidence regarding the inter-
action between CysLTs and GPR17 reported by Ren et al. ,[59]
with the authors affirming that when LTD4 was injected directly
into the third ventricle of mice, it was able to activate GPR17-
induced food intake. In contrast, administration of cangrelor
produced a significant decrease in food intake.
Buccioni and collaborators achieved similar results, although
their experiments were performed using different methodolo-
gies. In fact, uracil nucleotides and nucleotide sugars promot-
ed inhibition of cAMP production with EC50 values similar to
those reported by Ciana and co-workers.[53] Both laboratories
tested selective antagonists for both classes of receptor family
(CysLTRs and purinergic receptors), and the IC50 values (manu-
script in preparation) obtained from an [35S]GTPgS binding
assay[8] and a GloSensor cAMP assay[53] showed a strong corre-
lation.
The ability of GPR17 to bind purinergic ligands was also
demonstrated by Temporini and co-workers through a new
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technique: frontal affinity chromatography-mass spectrometry
(FAC-MS). A liquid chromatography stationary phase contain-
ing immobilized membranes from 1321N1 cells expressing
GPR17 was used to reveal the specific interaction between the
receptor and three ligands that were reported to interact with
GPR17: cangrelor (a P2Y12/13R antagonist), MRS2179 (a P2Y1R
antagonist), and the agonist UDP (Table 1).[8] The validity of the
experiment was confirmed by the agreement of the calculated
dissociation constant (Kd) values with previously reported
data.[60] This technique was also used to screen a library of nu-
cleotide derivatives in order to select high-affinity ligands and
to identify a lead compound for the generation of new potent
and selective ligands. The chromatographic results were vali-
dated with the [35S]GTPgS binding assay. In particular, the li-
brary for GPR17 ligands was selected, taking into account the
chemical structures of the three above-mentioned known re-
ceptor ligands: cangrelor, MRS2179, and UDP. A series of ATP
derivatives, substituted at the 2- and/or N6-position, were
tested (3–7). Furthermore, in order to study the importance of
the 3-nitrogen purine ring, the 2,N6-disubstituted ATP 3-deaza
analogue was evaluated (5), in addition to a bisphosphate de-
rivative analogue of MRS2179 (2) and a 5-substituted UDP ana-
logue (1). The results are reported in Table 2. Comparing the
results obtained with FACS-MS with those obtained with
[35S]GTPgS, it is noted that the elution order of the analytes by
column is closely related to the activity obtained with the
binding assay, expressed as half-maximal response concentra-
tions (EC50) or half-maximal inhibition (IC50) values for agonists
and antagonists, respectively.[61]
Experimental results from Hennen and collaborators led to
conclusions different from those obtained by other research
groups. Hennen et al. tested some of the P2YR agonists men-
tioned above, but all of them were unable to activate GPR17.
This group also identified a small molecule, MDL29951
(Figure 3), that was able to activate the receptor with remark-
able selectivity, even in an environment of endogenous puri-
nergic receptors.[44,62] This molecule is the unique ligand whose
ability to activate GPR17 is undisputed. The effect of
MDL29951 was hampered by the CysLT1R antagonist pranlu-
kast. Unlike montelukast, which resulted in total inactivity,
Table 2. FAC-MS data in comparison with [35S]GTPgS binding results obtained for GPR17-IAM-II.[a]
Compound GPR17-IAM-II Compound GPR17-IAM-II
t [min][b] EC50 [nm]
[c] IC50 [nm]
[d] t [min][b] EC50 [nm]
[c] IC50 [nm]
[d]
2.69 1.140.2 mm 4.5 111
2.79 94548 4.77 1.70.1
3.55 58257 5.67 1.40.1
3.62 50829 10.6 0.70.02
3.69 1127 13.07 363 pm
[a] Columns: GPR17-IAM-II (19.5 million cells). [b] Breakthrough time of the ligand with immobilized GPR17. [c] Values in nm unless otherwise noted.
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pranlukast was able to inhibit GPR17 in a surmountable and
noncompetitive manner.
Data published by Jensen and co-workers were not able to
confirm the activation of GPR17 by CysLTR agonists.[12,54] These
authors performed [35S]GTPgS binding assays in two different
cell lines expressing the long or the short isoform of hGPR17,
but LTD4 did not bind to any of these isoforms. In addition,
Jensen and colleagues tested montelukast, previously reported
as an antagonist of both CysLT1R and GPR17,[11] but did not
observe any activity. Subsequently, the same compound was
tested as an inverse agonist on the two GPR17 isoforms, but it
did not suppress the constitutive activity of the receptor.
Different results were obtained when the ability of some
P2YR agonists to activate the two isoforms was tested. UDP,
UDP-galactose, and UDP-glucose activated hGPR17-S with EC50
values similar to those reported in literature for this isoform,[8]
while the two UDP-sugars were much less potent toward
hGPR17-L, and UDP was not able to activate this isoform at all.
In view of the fact that different research groups affirm that
GPR17 activation is antagonized by several P2YR ligands,[8,11, 57]
the P2Y12R antagonist ticlopidine was studied as inverse ago-
nist at GPR17. Ticlopidine was not able to antagonize the
effect of UDP-glucose or UDP-galactose, nor was it able to sup-
press the constitutive activities of the two isoforms.
Unlike previously reported results, Qi and collaborators as-
serted that neither purinergic nor CysLTRs ligands activate
GPR17. These researchers investigated receptor activation by
measuring inositol phosphate output, cAMP production inhibi-
tion, and Ca2+ mobilization in five different cell lines stably or
transiently expressing the receptor. Experiments were also per-
formed to co-express GPR17 and CysLT1R. In agreement with
Maekawa’s results, Qi and co-workers noted that when the two
receptors were co-expressed, a clear reduction in CysLT1R ac-
tivity was observed, along with a reduction in expression of
the same receptor at the cell surface, emphasizing that GPR17
behaves as a negative regulator of CysLT1R.[55] These data are
in agreement with a recent study by Maekawa et al. , which
demonstrated that GPR17 knockout mice demonstrate an in-
creased immune response to dust mites with augmented
levels of IgE and inflammatory cytokines, as they lack GPR17-
induced inhibition of CysLT1R activity, as previously report-
ed.[52,63]
Conclusions
Several questions remain unanswered. There is disagreement
regarding GPR17 ligand agonist or antagonist profiles, and the
role of this receptor in the pathologies of the nervous system
is not completely clarified. The identification of purinergic li-
gands, which include agonists and antagonists, and the small
molecule MDL29951, a GPR17 agonist, increased the possibility
of carrying out the investigation of GPR17 pathophysiological
role. Moreover, the activation of GPR17 by CysLTs is highly con-
troversial, even though Marschallinger and co-workers suggest
that the effects of montelukast on neurogenesis and cognition
are most likely mediated through inhibition of GPR17. On the
other hand, the high expression of this receptor in organs that
usually undergo ischemic damage, its key role in oligodendro-
genesis, and some available data on the up- or downregula-
tion of GPR17 during myelination induction make this receptor
a novel therapeutic tool in the treatment of demyelinating dis-
eases such as MS. In light of this information, it is very difficult
to unequivocally explain the inconsistencies regarding the nat-
ural ligands of GPR17. Research efforts should be focused on
clarifying the role of this receptor in neuropathology and in
discovering new compounds able to interact with GPR17.
Keywords: G protein-coupled receptors · leukotrienes ·
membrane proteins · myelination · oligodendrocyte precursor
cells (OPCs)
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The G Protein-Coupled Receptor
GPR17: Overview and Update
Potential CNS champion: Although the
controversy regarding the ligands that
interact with GPR17 still remains unclari-
fied, it is well known that this receptor
is involved in the differentiation of neu-
ronal cells, the myelination process, and
repair mechanisms following a brain
insult. Clearly, GPR17 could represent
a novel therapeutic target for the treat-
ment of demyelinating disorders and
development of promising anti-ischemic
agents.
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